HC Wainwright set a $4.00 price target on Alphatec (NASDAQ:ATEC) in a research note published on Tuesday, February 26th. The brokerage currently has a buy rating on the medical technology company’s stock.
ATEC has been the topic of several other research reports. Zacks Investment Research lowered Alphatec from a hold rating to a strong sell rating in a research note on Thursday, November 15th. ValuEngine upgraded Alphatec from a sell rating to a hold rating in a research note on Wednesday, January 2nd.
Shares of ATEC stock traded down $0.06 on Tuesday, hitting $2.64. 339,987 shares of the stock were exchanged, compared to its average volume of 747,830. The company has a debt-to-equity ratio of 1.42, a current ratio of 2.36 and a quick ratio of 1.48. The stock has a market capitalization of $114.08 million, a P/E ratio of -4.55 and a beta of 1.14. Alphatec has a fifty-two week low of $1.18 and a fifty-two week high of $4.21.
Alphatec (NASDAQ:ATEC) last released its earnings results on Thursday, March 7th. The medical technology company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.03). Alphatec had a negative return on equity of 85.82% and a negative net margin of 31.60%. The company had revenue of $25.34 million for the quarter. Equities analysts expect that Alphatec will post -0.62 EPS for the current year.
In other news, Director Evan Bakst bought 20,566 shares of the stock in a transaction dated Monday, March 11th. The shares were bought at an average price of $2.59 per share, for a total transaction of $53,265.94. Following the completion of the purchase, the director now owns 726,912 shares in the company, valued at $1,882,702.08. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Kelli Mari Howell bought 100,000 shares of the stock in a transaction dated Monday, March 11th. The shares were purchased at an average price of $2.59 per share, for a total transaction of $259,000.00. The disclosure for this purchase can be found here. 44.40% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP increased its stake in shares of Alphatec by 8.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 95,662 shares of the medical technology company’s stock worth $219,000 after purchasing an additional 7,705 shares during the period. Raymond James Financial Services Advisors Inc. grew its position in Alphatec by 49.2% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 29,063 shares of the medical technology company’s stock worth $67,000 after buying an additional 9,579 shares in the last quarter. Beacon Pointe Wealth Advisors LLC acquired a new stake in Alphatec during the fourth quarter worth approximately $36,000. Royce & Associates LP grew its position in Alphatec by 124.8% during the fourth quarter. Royce & Associates LP now owns 35,000 shares of the medical technology company’s stock worth $80,000 after buying an additional 19,432 shares in the last quarter. Finally, Suntrust Banks Inc. acquired a new stake in Alphatec during the fourth quarter worth approximately $58,000. Institutional investors own 18.57% of the company’s stock.
Alphatec Company Profile
Alphatec Holdings, Inc, a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures.
Read More: How to interpret a stock’s beta number
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.